Cantor Fitzgerald Expects Weaker Earnings for Sanara MedTech

Sanara MedTech Inc. (NASDAQ:SMTI) – Equities researchers at Cantor Fitzgerald cut their FY2025 EPS estimates for shares of Sanara MedTech in a research note issued to investors on Wednesday, March 26th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings of ($2.43) per share for the year, down from their prior forecast of ($0.98). Cantor Fitzgerald currently has a “Overweight” rating and a $46.00 price target on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share.

Separately, HC Wainwright boosted their price objective on Sanara MedTech from $50.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday.

Sanara MedTech Stock Performance

Shares of Sanara MedTech stock opened at $31.22 on Friday. The business has a 50-day simple moving average of $34.31 and a 200 day simple moving average of $33.77. Sanara MedTech has a one year low of $26.00 and a one year high of $39.08. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.23 and a quick ratio of 2.02. The firm has a market capitalization of $272.89 million, a price-to-earnings ratio of -31.54 and a beta of 1.37.

Sanara MedTech (NASDAQ:SMTI) last announced its quarterly earnings data on Tuesday, March 25th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01. The firm had revenue of $26.31 million for the quarter, compared to analyst estimates of $22.75 million. Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%.

Hedge Funds Weigh In On Sanara MedTech

Large investors have recently added to or reduced their stakes in the business. Marshall Wace LLP bought a new position in shares of Sanara MedTech in the fourth quarter valued at approximately $1,005,000. Fifth Third Bancorp purchased a new position in Sanara MedTech during the 4th quarter worth $898,000. Renaissance Technologies LLC grew its stake in shares of Sanara MedTech by 152.9% in the 4th quarter. Renaissance Technologies LLC now owns 35,400 shares of the company’s stock worth $1,175,000 after acquiring an additional 21,400 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Sanara MedTech by 234.5% in the 4th quarter. JPMorgan Chase & Co. now owns 13,574 shares of the company’s stock worth $451,000 after acquiring an additional 9,516 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Sanara MedTech by 116.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 15,925 shares of the company’s stock valued at $529,000 after purchasing an additional 8,567 shares during the last quarter. Institutional investors own 8.10% of the company’s stock.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.